Industry News

FDA approves Gilead Sciences drug for 3 cancers
Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert IUD
Seven pharma companies offer up compounds to UK researchers
Can PGXL Informatics Make Drugs Safer and More Effective?
Teva Completes Acquisition of Labrys: Opens Door to a Strong and Novel Migraine Prevention and Treatment Franchise within its CNS Portfolio
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements Corrects Allergan's False Statements Regarding Bausch + Lomb Performance
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in the United States
American Regent Reports Sales Growth of Injectafer
DHL launches new logistics service for life sciences products handled at extremely low temperatures
FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo� Sanofi
Global Point of Care Diagnostics Market: Industry Analysis, Size, Share, Growth and Forecast 2018
United States : PFIZER to acquire INNOPHARMA
Teen's death puts focus on caffeine powder dangers
Salix Pharmaceuticals to Merge with Cosmo Technologies to Form Salix Pharmaceuticals
Baxter Updates on Acquisition of AesRx
Forum Pharmaceuticals Appoints Boisclair as VP, Regulatory Affairs
As Testosterone Lawsuits Are Filed In The U.S., Canada Warns of Possible Cardiac Risks Associated With Testosterone Medication
United States : US FDA grants approval to SALIX and PHARMING for Ruconest
Summit Medical, Inc. Receives FDA 510(k) Clearance for Additional Sterilization Cycles
Actavis Seeks FDA Approval to Market Dalfampridine Extended-Release Tablets
Laboratory Heads from World-Renowned Academic Medical Centers Urge OMB Not to Release FDA Guidance on the Regulation of Laboratory-Developed Tests...
AbbVie, Shire agree on approx $55 billion combination, will form new UK incorporated company
AbbVie, Shire agree on approx $55 billion combination, will form new UK incorporated company
Laboratory Heads from Major Academic Medical Centers Urge OMB Not to Release FDA Guidance on the Regulation of LDTs.
Can PGXL Informatics Make Drugs Safer and More Effective?